Adaptive Biotechnologies Corp (ADPT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Adaptive Biotechnologies Corp stock (ADPT) is currently trading at $13.90. Adaptive Biotechnologies Corp PS ratio (Price-to-Sales) is 7.55. Analyst consensus price target for ADPT is $20.86. WallStSmart rates ADPT as Sell.
- ADPT PE ratio analysis and historical PE chart
- ADPT PS ratio (Price-to-Sales) history and trend
- ADPT intrinsic value — DCF, Graham Number, EPV models
- ADPT stock price prediction 2025 2026 2027 2028 2029 2030
- ADPT fair value vs current price
- ADPT insider transactions and insider buying
- Is ADPT undervalued or overvalued?
- Adaptive Biotechnologies Corp financial analysis — revenue, earnings, cash flow
- ADPT Piotroski F-Score and Altman Z-Score
- ADPT analyst price target and Smart Rating
Adaptive Biotechnologies Corp
📊 No data available
Try selecting a different time range
Smart Analysis
Adaptive Biotechnologies Corp (ADPT) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Adaptive Biotechnologies Corp (ADPT) Key Strengths (3)
Revenue surging 51.00% year-over-year
100.89% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Adaptive Biotechnologies Corp (ADPT) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 9.6x book value
Premium valuation at 7.5x annual revenue
Supporting Valuation Data
Adaptive Biotechnologies Corp (ADPT) Detailed Analysis Report
Overall Assessment
This company scores 30/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 3 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 1.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own., Market Cap. Growth metrics are encouraging with Revenue Growth at 51.00%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (7.55), Price/Book (9.56) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -27.80%, Operating Margin at -17.80%, Profit Margin at -21.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -27.80% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 51.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ADPT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ADPT's Price-to-Sales ratio of 7.55x trades at a deep discount to its historical average of 29.52x (35th percentile). The current valuation is 95% below its historical high of 140.48x set in Aug 2019, and 221% above its historical low of 2.35x in Apr 2024. Over the past 12 months, the PS ratio has expanded from ~6.6x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Adaptive Biotechnologies Corp (ADPT) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Adaptive Biotechnologies Corp is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 277M with 51% growth year-over-year. The company is currently unprofitable, posting a -21.5% profit margin.
Key Findings
Revenue growing at 51% YoY, reaching 277M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Generating 1M in free cash flow and 2M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -21.5% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Growth sustainability: can Adaptive Biotechnologies Corp maintain 51%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 2.30, so expect amplified moves relative to the broader market.
Debt management: total debt of 281M is significantly higher than cash (70M). Monitor refinancing risk.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Adaptive Biotechnologies Corp.
Bottom Line
Adaptive Biotechnologies Corp is a high-conviction growth story with revenue accelerating at 51% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -21.5% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Adaptive Biotechnologies Corp(ADPT)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company is headquartered in Seattle, Washington.